News & Updates
Filter by Specialty:
Show Multimedia Only

TRAILBLAZER-ALZ 6 updates support new donanemab dosing schedule for AD
10 Oct 2025
byAudrey Abella
In the 18-month results from the phase IIIb TRAILBLAZER-ALZ 6 trial, the newly recommended dosing schedule of donanemab results in a significant reduction in the incidence of amyloid-related imaging abnormalities with effusion/oedema (ARIA-E) compared with standard dosing in adults with early symptomatic Alzheimer’s disease (AD).